Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00976404 · ClinicalTrials.gov registry record · Phase 2
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
A Phase 2 study of HIV Infection, sponsored by Robert L. Murphy.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 3
- Study locations
NCT00976404 is a Phase 2 study of HIV Infection that has completed, run by Robert L. Murphy. The registered enrollment target is 28 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00976404, a Phase 2 study of HIV Infection, has completed, sponsored by Robert L. Murphy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this study is to discover a new approach in which human immunodeficiency virus (HIV) can be eradicated from an infected individual by intensified antiretroviral treatment coupled with immunomodulation. The hypothesis is that eradication is possible only if very potent antiretroviral drugs are delivered in conjunction with an immunomodulatory agent that simultaneously attack the viral reservoirs.
Conditions Studied
Interventions
- BIOLOGICAL DNA + HIV-rAd5 vaccine
- DRUG ART intensification (raltegravir)
- DRUG ART intensification (maraviroc)
Study Locations (3)
California
- University of California San Francisco - San Francisco
Illinois
- Northwestern University - Chicago
New York
- Cornell University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00976404
The ClinicalTrials.gov registry entry for NCT00976404 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (88% lower). The listed sponsor is Robert L. Murphy, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 3 interventions - of which DNA + HIV-rAd5 vaccine is the first listed.
NCT00976404 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00976404 about?
NCT00976404 is a clinical study titled "Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir". The objective of this study is to discover a new approach in which human immunodeficiency virus (HIV) can be eradicated from an infected individual by intensified antiretroviral treatment coupled with immunomodulation. The hypothesis is that eradication is possible only if very potent antiretroviral...
What is the current status of trial NCT00976404?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2009-11. Estimated completion is 2014-06.
What conditions does trial NCT00976404 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT00976404?
The interventions under investigation include: DNA + HIV-rAd5 vaccine (BIOLOGICAL), ART intensification (raltegravir) (DRUG), ART intensification (maraviroc) (DRUG).
Who is sponsoring clinical trial NCT00976404?
This trial is sponsored by Robert L. Murphy, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00976404 being conducted?
This trial has 3 study locations across California, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
ACTIVE NOT RECRUITING · Phase 2
-
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
COMPLETED · Phase 2
-
Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
COMPLETED · Phase 2
-
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.